Dupret Daniel 4
4 · AzurRx BioPharma, Inc. · Filed Jul 18, 2018
Insider Transaction Report
Form 4
Dupret Daniel
Chief Scientific Officer
Transactions
- Award
Common Stock
2018-07-12+15,000→ 15,000 total - Award
Options
2018-07-12+60,000→ 60,000 totalExercise: $3.04Exp: 2023-06-28→ Common Stock (60,000 underlying)
Footnotes (2)
- [F1]Represents grant of restricted stock. Shares shall vest in increments as follows: 7,500 shares upon the acceptance of a U.S. IND for MS1819, and 7,500 shares upon the the first CF patient dosed with MS1819 anywhere in the globe.
- [F2]Options with respect to 30,000 shares vest upon the acceptance of a U.S. IND for MS 1819, and the remaining 30,000 shares vest upon the the first CF patient dosed with MS1819 anywhere in the globe.